Blood filters in children with COVID-19 and acute kidney injury: A review

Rupesh Raina, Sidharth Kumar Sethi, Ronith Chakraborty, Siddhartha Singh, Sharon Teo, Amrit Khooblall, Giovanni Montini, Timothy Bunchman, Rezan Topaloglu, Hui Kim Yap

Research output: Contribution to journalReview articlepeer-review


COVID-19 has challenged the global healthcare system through rapid proliferation and lack of existing treatment resulting in over 180 million cases and 3.8 million deaths since December 2019. Although pediatric patients only comprise 1%–2% of diagnosed cases, their incidence of acute kidney injury ranges from 8.2% to 18.2% compared to 49% in adults. Severe infection, initiated by dysregulated host response, can lead to multiorgan failure. In this review, we focus on the use of various blood filters approved for use in pediatric kidney replacement therapy to mitigate adverse effects of severe illness. Therapeutic effects of these blood filters range from cytokine removal (CytoSorb, HA330, HCO/MCO), endotoxin removal (Toraymyxin, CPFA), both cytokine and endotoxin removal (oXiris), and nonspecific removal of proteins (PMMA) that have already been established and can be used to mitigate the various effects of the cytokine storm syndrome in COVID-19.

Original languageEnglish
Pages (from-to)566-582
Number of pages17
JournalTherapeutic Apheresis and Dialysis
Issue number3
Publication statusPublished - Jun 2022


  • blood filters
  • COVID-19
  • CytoSorb
  • oXiris

ASJC Scopus subject areas

  • Hematology
  • Nephrology


Dive into the research topics of 'Blood filters in children with COVID-19 and acute kidney injury: A review'. Together they form a unique fingerprint.

Cite this